When Chemotherapy Is Not Enough-Management of Prostatic Embryonal Rhabdomyosarcoma in an Infant

Urology. 2018 Mar:113:200-202. doi: 10.1016/j.urology.2017.10.044. Epub 2017 Nov 16.

Abstract

A baby boy was diagnosed with embryonal rhabdomyosarcoma causing left hydroureteronephrosis. A loop ureterostomy was performed, and the infant was treated per the RMS13 protocol. After 3 months of chemotherapy, the infant's tumor burden increased, and he underwent radical cystoprostatectomy and right-to-left transureteroureterostomy (end-to-end fashion utilizing the distal limb of his ureterostomy). This innovative method was utilized because the infant's tumor burden was too large to be treated effectively and safely with radiation. One year later, the infant has no evidence of disease. This demonstrates that optimal management of rhabdomyosarcoma is still unknown; therefore, each child warrants an individualized approach for optimal outcomes.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Disease Progression
  • Follow-Up Studies
  • Humans
  • Hydronephrosis / diagnosis
  • Hydronephrosis / etiology
  • Infant
  • Male
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Postoperative Care / methods
  • Prostatectomy / methods*
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Rhabdomyosarcoma, Embryonal / diagnostic imaging*
  • Rhabdomyosarcoma, Embryonal / pathology
  • Rhabdomyosarcoma, Embryonal / therapy*
  • Risk Assessment
  • Treatment Failure
  • Treatment Outcome
  • Ureterostomy / methods*